ONE-WAYOngoing theme · still written in the latest filings
Risk from unestablished immunocell therapy prices and price competition
Risk that no standard prices have been established for immunocell therapy treatment and processing fees, and that service prices and profitability will decline as competition intensifies.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.